- Home
- RF vs BIIB Comparison
RF vs BIIB Comparison
Compare RF & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RF
- BIIB
- Stock Information
- Founded
- RF 1970
- BIIB 1978
- Country
- RF United States
- BIIB United States
- Employees
- RF N/A
- BIIB N/A
- Industry
- RF Major Banks
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- RF Finance
- BIIB Health Care
- Exchange
- RF Nasdaq
- BIIB Nasdaq
- Market Cap
- RF 23.8B
- BIIB 25.1B
- IPO Year
- RF N/A
- BIIB 1991
- Fundamental
- Price
- RF $23.28
- BIIB $146.79
- Analyst Decision
- RF Buy
- BIIB Buy
- Analyst Count
- RF 18
- BIIB 27
- Target Price
- RF $27.33
- BIIB $252.20
- AVG Volume (30 Days)
- RF 7.2M
- BIIB 1.5M
- Earning Date
- RF 01-17-2025
- BIIB 02-11-2025
- Dividend Yield
- RF 4.29%
- BIIB N/A
- EPS Growth
- RF N/A
- BIIB 10.05
- EPS
- RF 1.77
- BIIB 11.06
- Revenue
- RF $6,556,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- RF N/A
- BIIB N/A
- Revenue Next Year
- RF $5.36
- BIIB N/A
- P/E Ratio
- RF $13.12
- BIIB $13.27
- Revenue Growth
- RF N/A
- BIIB N/A
- 52 Week Low
- RF $17.42
- BIIB $146.58
- 52 Week High
- RF $27.96
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- RF 24.67
- BIIB 23.28
- Support Level
- RF $24.77
- BIIB $148.60
- Resistance Level
- RF $25.28
- BIIB $154.24
- Average True Range (ATR)
- RF 0.56
- BIIB 3.89
- MACD
- RF -0.38
- BIIB -0.31
- Stochastic Oscillator
- RF 0.83
- BIIB 1.15
About RF Regions Financial Corporation
Regions Financial is a regional bank headquartered in Alabama, with branches primarily in the Southeastern and Midwestern United States. Regions primarily provides traditional commercial and retail banking and also offers mortgage services, asset management, wealth management, securities brokerage, and trust services.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.